

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

F9

RRID:CVCL_0259

Type: Cell Line

Proper Citation

CLS Cat# 400174, RRID:CVCL_0259

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0259

Proper Citation: CLS Cat# 400174, RRID:CVCL_0259

Description: Cell line F9 is a Cancer cell line with a species of origin Mus musculus (Mouse)

Sex: Male

Disease: Mouse teratocarcinoma

Defining Citation: [PMID:61803](#), [PMID:214238](#), [PMID:2412863](#), [PMID:4521215](#), [PMID:6479493](#)

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: F9

Cross References: BTO:BTO_0000095, CLO:CLO_0002988, CLO:CLO_0050537, CLO:CLO_0050539, EFO:EFO_0002053, MCCL:MCC:0000150, CLDB:cl1198, CLDB:cl1199, CLDB:cl1200, CLDB:cl1201, CLDB:cl4950, ATCC:CRL-1720, CCRID:1101MOU-PUMC000276, CCRID:3101MOUTCM4, ChEMBL-Cells:ChEMBL3307489, ChEMBL-Targets:ChEMBL614296, CLS:400174, DSMZ:ACC-112, DSMZCellDive:ACC-112, ECACC:85061803, ICLC:ATL99006, JCRB:JCRB0721, KCLB:21720, PubChem_Cell_line:CVCL_0259, RCB:RCB1555, RCB:RCB2643, TKG:TKG 0519, TOKU-E:1176, Wikidata:Q54833162

ID: CVCL_0259

Vendor: CLS

Catalog Number: 400174

Hierarchy: cvcl_5572

Record Creation Time: 20220624T070547+0000

Record Last Update: 20260830T000506+0000

Ratings and Alerts

No rating or validation information has been found for F9.

No alerts have been found for F9.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Zhou Y, et al. (2026) Murine Embryonic Stem Cells Possess Distinct E2F Activity That Activates Tumor Suppressor Promoter Elements. Genes to cells : devoted to molecular & cellular mechanisms, 31(3), e70121.

Pfister SK, et al. (2026) Immunocompetent Mouse Models of Cancer Reveal the Superiority of Cellular Targets over Stromal Targets for the Development of Anticancer Bispecific Antibodies. Molecular cancer therapeutics, 25(2), 310.

Rotta G, et al. (2025) Combinatorial treatment with upadacitinib abrogates systemic toxicity of a tumor-targeted IL-2 fusion protein. Journal for immunotherapy of cancer, 13(5).

Da Silva AJ, et al. (2024) Proteomic profiling identifies a direct interaction between heat shock transcription factor 2 and the focal adhesion adapter talin-1. The FEBS journal, 291(21), 4830.

Noguchi Y, et al. (2024) In vivo CRISPR screening directly targeting testicular cells. Cell genomics, 4(3), 100510.

Tan D, et al. (2021) Quantitative control of noise in mammalian gene expression by dynamic histone regulation. eLife, 10.

Pan M, et al. (2021) Interactome analysis reveals endocytosis and membrane recycling of EpCAM during differentiation of embryonic stem cells and carcinoma cells. iScience, 24(10), 103179.

Lake RJ, et al. (2020) A Novel Flow Cytometric Assay to Identify Inhibitors of RBPJ-DNA Interactions. SLAS discovery : advancing life sciences R & D, 25(8), 895.

Wolf G, et al. (2020) KRAB-zinc finger protein gene expansion in response to active retrotransposons in the murine lineage. *eLife*, 9.

AlAbdi L, et al. (2020) Oct4-Mediated Inhibition of Lsd1 Activity Promotes the Active and Primed State of Pluripotency Enhancers. *Cell reports*, 30(5), 1478.

Wang HF, et al. (2020) Defining Essential Enhancers for Pluripotent Stem Cells Using a Features-Oriented CRISPR-Cas9 Screen. *Cell reports*, 33(4), 108309.

Bui PL, et al. (2019) Template Activating Factor-1 ? Regulates Retroviral Silencing during Reprogramming. *Cell reports*, 29(7), 1909.